Actively Recruiting
Long-term Safety and Tolerability of Zigakibart in Adults with IgA Nephropathy An Open-label Extension Multicenter Study
Led by Novartis Pharmaceuticals · Updated on 2026-08-17
220
Participants Needed
26
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the long-term safety and tolerability of zigakibart in adults with primary immunoglobulin A nephropathy IgAN. This open-label extension study includes participants who have completed previous zigakibart trials, aiming to gather extended safety information and assess the drugs effects over time. The study is sponsored by Novartis Pharmaceuticals and continues from earlier phase 12 and phase 3 studies. Participants will receive zigakibart as a solution for subcutaneous injection at a dose of 600 mg every two weeks. This is a single-group, open-label study where all participants receive the active treatment. The study monitors safety and tolerability through various assessments over several years, including serum drug levels and immunoglobulin measurements. Participants are followed for up to approximately five years to observe any adverse events and changes in kidney function. During the study, participants will have scheduled visits for clinical evaluations, laboratory testing, and monitoring of adverse events. Key measurements include urinary protein to creatinine ratio UPCR, estimated glomerular filtration rate eGFR, immunoglobulin levels, and detection of anti-drug antibodies. Safety labs and vital signs will be tracked throughout. The studys main outcomes focus on the number of participants experiencing adverse events, with follow-up continuing 24 weeks after treatment ends. Overall participation may last up to six years, including treatment and post-treatment monitoring.
CONDITIONS
Brief Title
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here